In OPTIC, response to treatment was dose dependent, with 51.6%, 35.5%, and 25.3% of patients with T315I-mutated CML-CP at ponatinib starting doses of 45, 30, and 15 mg, respectively, achieving this response by 12 months and 60.0%, 25.0%, and 10.5%, respectively, by 3 years [14, 16]. This evidence concerns the gene CP and chronic myelogenous leukemia, BCR-ABL1 positive.